Fannie Mae, Freddie Mac shares tumble after conservatorship comments
MAINZ, Germany - BioNTech SE (NASDAQ:BNTX) reported first quarter 2025 financial results that showed lower-than-expected revenue but a narrower loss than analysts anticipated on Monday.
The company’s stock was down -0.26% in premarket trading following the earnings release.
The German biotechnology company posted revenue of €182.8 million for the quarter, falling short of the €204.08 million consensus estimate. However, BioNTech’s loss per share of €1.73 was better than the €2.00 loss analysts had forecast.
Revenue declined slightly YoY from €187.6 million in Q1 2024, primarily driven by lower COVID-19 vaccine sales as demand has waned. The company said revenues were "mainly driven by revenues derived from BioNTech’s COVID-19 vaccine collaboration."
BioNTech reported a net loss of €415.8 million for the quarter, wider than the €315.1 million loss in the same period last year. The increased loss was attributed to higher research and development expenses as the company advances its oncology pipeline.
"Our revenues for the first quarter reflect the seasonal demand for COVID-19 vaccines and are in line with our expectations," said Jens Holstein, CFO of BioNTech.
The company reaffirmed its full-year 2025 revenue guidance of €1.7 billion to €2.2 billion.
CEO Ugur Sahin highlighted progress in the company’s oncology programs, stating: "We demonstrated continued execution against our strategic focus areas, highlighted by data updates for our PD-L1xVEGF-A bispecific antibody candidate BNT327 and the progress in clinical evaluation of our focus programs and combination treatment approaches."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.